StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$6.70−0.43 (-6.03%)

Close on Nov 18, 2026Market cap $359.32MP/E –Yield –

Avalo Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Avalo Therapeutics's pe ratio was 1.2× on Jul 31, 2025, against 330.8× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jul 31, 20251.2×−39.8
2018Oct 31, 201841.0×−278.8
2017Dec 29, 2017319.8×–

More Avalo Therapeutics figures

See a number that looks wrong?